Anti-HER2 × anti-DOTA-Bn bsAb and lutetium-177-labeled hapten based fractionated 3-cycle PRIT resulted in successful tumor targeting of HER2 positive BT-474 human breast cancer xenografts (Figure 3) and demonstrated successful antitumor efficacy. The gene discussed is ERBB2; the disease is breast cancer.